艾力斯：2025年营收51.72亿元，净利润同比增52.55%

Core Insights - The company reported a total operating revenue of 5,171.71 million yuan for the fiscal year 2025, representing a year-on-year growth of 45.36% [1] - The net profit attributable to the parent company was 2,181.29 million yuan, showing a year-on-year increase of 52.55% [1] - As of the end of the reporting period, total assets reached 7,878.66 million yuan, an increase of 33.17% compared to the beginning of the year [1] - The equity attributable to the parent company's owners was 7,075.39 million yuan, reflecting a growth of 33.93% from the start of the year [1] - The growth in performance is primarily attributed to the increased sales of the core product, Fumetinib Mesylate Tablets, along with effective cost reduction measures implemented by the company [1]